Gavreto (Pralsetinib) Patent Expiration, LOE Window & CMS Spending

Gavreto (Pralsetinib) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2042-07-07 (last listed 2043-04-19), 0 AB generics, $16.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRigel Pharmaceuticals
FDA Application & PathwayN213721 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2042-07-07
Last Listed Patent or Exclusivity Date2043-04-19
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16.8M
2024 Medicare Part D Spend$14.9M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.9% 2-yr change)